Navigation Links
FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis

NORTHBROOK, Ill., July 16, 2014 /PRNewswire/ -- Astellas today announced that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis, a life-threatening, invasive fungal infection.

A product that is granted QIDP status receives a priority review and a five-year extension of market exclusivity in the United States. Previously, isavuconazole received QIDP designation for invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). The incentives for all three conditions were granted under the 2012 U.S. Generating Antibiotic Incentives Now (GAIN) Act as a part of the FDA Safety and Innovation Act.

"The need to treat serious fungal infections can be one of life or death. This QIDP designation, along with the previous two we have received, emphasizes how important it is to patients and their families that products are available to treat these infections," said Bernie Zeiher, Executive Vice President, Global Development and Therapeutic Area Head of Infectious Disease at Astellas.

About Isavuconazole
Isavuconazole (drug substance: isavuconazonium sulfate) is an investigational once-daily intravenous and oral broad-spectrum antifungal being developed for the treatment of severe invasive and life-threatening fungal infections. Isavuconazole is the active moiety of the prodrug isavuconazonium sulfate. Information regarding isavuconazole ongoing clinical trials is available at  

Isavuconazole demonstrated in-vitro and in-vivo coverage of a broad range of yeasts (such as Candida species) and molds (such as Aspergillus species) as well as activity against emerging and often fatal molds including those that cause mucormycosis.

In the Phase 3 invasive aspergillosis study, isavuconazole demonstrated non-inferiority to voriconazole on the primary endpoint of all-cause mortality at day 42.  The treatment-emergent adverse events for isavuconazole were statistically fewer relative to voriconazole in the System Organ Classes of hepatobiliary, skin and eye disorders. In both treatment groups, the most common treatment emergent adverse events were nausea, vomiting, pyrexia (fever) and diarrhea.

Isavuconazole is being co-developed with Basilea Pharmaceutica International Ltd.

About Astellas Infectious Disease
Astellas' commitment to the field of infectious diseases is an active one. We're expanding the knowledge base of this therapeutic area and empowering physicians to make evidence-based clinical decisions.

Our proud history of collaborating with investigators around the world provides ideal environments to study compounds that have the potential for significant breakthroughs and allows us to generate and publish key information on our advances. In fact, Astellas has performed some of the world's largest clinical trials in fungal infections.

About Astellas
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. The headquarters for the Americas is located in Northbrook, Ill. For more information on Astellas, please visit our website at

Logo -

SOURCE Astellas
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Orphan Drug Designation to Omeros OMS721 for Complement-Mediated Thrombotic Microangiopathies
2. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
3. Auxilium Pharmaceuticals, Inc. Announces Court Grants Upsher-Smith Laboratories Motion For Summary Judgment
4. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Aspergillosis
5. RadSite Grants Accreditation to First Wave of MIPPA Program Applicants
6. NASDAQ Grants China Jo-Jo Drugstores 180-Day Extension to Regain Compliance with Bid Price Requirement
7. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
8. FDA Grants 510(k) Clearance for Innovative Fuse Gastroscope from EndoChoice
9. Philanthropic Grants, Product Launches, Promising Partnerships, and Customer Satisfaction Rankings - Research Report on CVS Caremark, Walgreens, McKesson, AmerisourceBergen, and Cardinal Health
10. Life Technologies Awards Digital PCR Innovation Grants to Five Research Labs
11. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
Post Your Comments:
(Date:11/30/2015)... 2015 iCAD, Inc. (Nasdaq: ICAD ... latest solutions for advanced image analysis and workflow ... the Radiological Society of North American (RSNA) 2015 ... from November 29 to December 4, 2015. The ... an automated breast density assessment solution, PowerLook® Advanced ...
(Date:11/30/2015)... 30, 2015 Varian Medical Systems (NYSE: VAR ) ... partnership with Apollo Hospitals Group, the largest hospital chain in ... train radiation technologists in the country. The MoU was signed by ... and Ashok Kakkar , Varian,s India ... India , Varian intends to deploy its Access to ...
(Date:11/30/2015)... Nov. 30, 2015  Precision Image Analysis Inc. ... pleased to announce a dramatic expansion of its ... Building on its ISO-9001:2008 certification for its Quality ... Core Lab protocols and procedures. This expansion enables ... activities.  Their Core Lab services include design and ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed ... of Glen Ridge, NJ. He has both advanced training and considerable experience ... is also an expert in cosmetic dentistry. He is an active Spear ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... Poison Control Centers’ National Poison Data System (NPDS) reveals that in 2014, someone ... 3 million cases, over two million of which were human exposure cases. , ...
(Date:11/30/2015)... ... 2015 , ... The Foundation for Breast and Prostate Health ... forces with the award-winning creator and writer of Downton Abbey Julian Fellowes to ... the Union League of Philadelphia. , The benefit, titled “An Evening with ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to RF Safe, ... senior scientist at Consumer Reports as supporting a “A Call for Clarity” on ... , The original Nov 2015 CR story titled, “Does Cell-Phone Radiation Cause Cancer?” ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., ... womb. "My last baby had high blood pressure due to loud noises," she said, ... their babies from noise pollution as well as radio waves and microwaves." , The ...
Breaking Medicine News(10 mins):